Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Biotechnology

Arkuda Therapeutics

Arkuda Therapeutics' headquarters in Cambridge, MA, United States

Gerhard Koenig

Jim Lanter

Irena Webster

Mike Esposito

Jean-François Blain

Pascale Witz

Bruce Booth

Christopher O’Donnell

Raymond J. Kelleher

The Leadership Team at Arkuda Therapeutics is responsible for guiding the company's strategic vision and overseeing the development of innovative therapies targeting neurodegenerative diseases. Comprising experts in neurobiology and medicinal chemistry, they collaborate to drive research initiatives, ensure scientific excellence, and foster partnerships that enhance the advancement of therapies based on insights into progranulin and lysosomal biology.

Leadership Team

The Science and Research team at Arkuda Therapeutics drives the discovery and development of novel therapies targeting progranulin and lysosomal pathways to combat neurodegenerative diseases. Comprised of specialists in neurobiology, medicinal chemistry, pharmacology, and toxicology, the team conducts cutting-edge research, preclinical studies, and drug development to advance Arkuda's pipeline of therapeutic candidates.

Arkuda Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Science and Research

Offices

Arkuda Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Science and Research

Offices

Related companies